Medical Condition News

RSS

DNA interval in unexplored region of human genome increases risk for coronary artery disease

Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory have learned how an interval of DNA in an unexplored region of the human genome increases the risk for coronary artery disease, the leading cause of death worldwide.

23 Feb 2010

Slightly to moderately elevated CRP levels in patients undergoing CABG surgery: Implications

A new study published in the March issue of Anesthesiology raises awareness for an additional risk category for patients undergoing routine coronary artery bypass surgery - low to moderate levels of inflammation.

23 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.

23 Feb 2010

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure Ltd., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., has received notice of allowance from the US Patent Office for its two key patent applications covering methods of use and compositions covering the use of betahistine with olanzapine for the mitigation of the serious weight gain associated as a side effect of the antipsychotic drug.

23 Feb 2010

Older diabetes patients with high stress levels are more likely to experience memory loss

Researchers at the University of Edinburgh studied more than 900 men and women aged between 60 and 75 with type-2 diabetes, which tends to be common after the age of 40.

23 Feb 2010

Lilly, Merck, Pfizer collaborate to accelerate research on commonly-diagnosed cancer

Eli Lilly and Company, Merck (also known as Merck Sharp & Dohme (MSD) outside the USA and Canada), and Pfizer Inc. today announced the formation of the Asian Cancer Research Group, Inc., an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia.

23 Feb 2010

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

When head and neck tumors - from sinus tumors to acoustic neuromas attached to the hearing and balance nerve at the base of the skull - are located in close proximity to such sensitive areas such as the brain and eyes, they are particularly dangerous due to possible brain injury, visionary risk or hearing loss.

23 Feb 2010

More research needed for osteoporosis treatments

Dr. Angelo Malamis says that 90 percent of his patients who have undergone a treatment called balloon kyphoplasty for vertebral fractures report significant reductions in pain and disability.

23 Feb 2010

Newborn Possibilities program for babies at-risk for neurological injury

For every 1,000 children born in the U.S. today, two to three are at risk for developing cerebral palsy because of injuries to the brain that may have occurred prior to or during birth. There is currently no cure for cerebral palsy, but Newborn Possibilities is a first-of-its-kind program recently launched in Tucson, which may offer new options for newborns at-risk for neurological injury.

23 Feb 2010

Multidisciplinary Head and Neck Cancer Symposium in Phoenix

The Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM, will host two news briefings on top head and neck cancer research from its meeting February 25-27, 2010, in Phoenix.

23 Feb 2010

Unique resource for families facing hereditary breast and ovarian cancer

When she was forty-two, Joi Morris learned that she has a genetic mutation on a gene known as BRCA2. This meant that her risk of getting breast cancer could be as high as 84 percent by age seventy, and that her risk for ovarian cancer was also high.

23 Feb 2010

Committee calls for strategies to curb hypertension

Public health officials and health care providers need to step up their efforts to reduce Americans' increasing rates of high blood pressure and better treat those with the condition, which triggers more than one-third of heart attacks and almost half of heart failures in the United States each year, says a new report from the Institute of Medicine.

23 Feb 2010

Combination of MRI and mammography reduces mortality rate in high-risk women

Annual breast cancer screening with both mammography and magnetic resonance imaging (MRI) is likely to be a cost-effective way to improve life expectancy in women with an increased risk of breast cancer, according to a new study published in the March issue of Radiology.

23 Feb 2010

Pulmonx to raise new funding for global launch of Zephyr EBV and Chartis Pulmonary Assessment System

Pulmonx, an emerging leader in interventional pulmonology, announced today that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr® Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System. Both products are CE marked and cleared for sale in Europe and other major international markets.

23 Feb 2010

Acute stroke care and clinical outcomes improve substantially with stroke program

Acute stroke care and clinical outcomes have improved significantly at hospitals participating in the American Heart Association/American Stroke Association's Get With The Guidelines-Stroke program, according to a large study in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association.

23 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

DURECT, Nycomed amend POSIDUR Development and License Agreement

DURECT Corporation announced today that Nycomed and DURECT have amended the Development and License Agreement entered into between the parties in 2006 covering the development and commercialization of POSIDUR™ (also known as SABER™-Bupivacaine or OPTESIA™), an investigational drug for the treatment of post-surgical pain.

23 Feb 2010

Star Scientific seeks FDA marketing approval for Ariva-BDL dissolvable tobacco lozenge

Star Scientific, Inc. announced that on Friday, February 19 the company filed an application with the Food & Drug Administration for approval to market Ariva-BDL™ as a "modified risk" tobacco product under the Family Smoking Prevention and Tobacco Control Act of 2009. This submission is the first such application to be filed with the Tobacco Products Center of the FDA, which has been established to oversee all aspects of tobacco regulation outlined in the 2009 Act.

23 Feb 2010

MRI: An efficient diagnostic tool for testicular cancer

Researchers have found that non-invasive magnetic resonance imaging (MRI) is a good diagnostic tool for the evaluation and staging of testicular cancer and may improve patient care by sparing some men unnecessary surgery, according to a study in the March issue of the American Journal of Roentgenology.

23 Feb 2010

Medical Condition News

DNA interval in unexplored region of human genome increases risk for coronary artery disease

Slightly to moderately elevated CRP levels in patients undergoing CABG surgery: Implications

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Older diabetes patients with high stress levels are more likely to experience memory loss

Lilly, Merck, Pfizer collaborate to accelerate research on commonly-diagnosed cancer

Head and neck tumors in close proximity to sensitive areas may lead to brain injury, visionary risk or hearing loss

More research needed for osteoporosis treatments

Newborn Possibilities program for babies at-risk for neurological injury

Multidisciplinary Head and Neck Cancer Symposium in Phoenix

Unique resource for families facing hereditary breast and ovarian cancer

Committee calls for strategies to curb hypertension

Combination of MRI and mammography reduces mortality rate in high-risk women

Pulmonx to raise new funding for global launch of Zephyr EBV and Chartis Pulmonary Assessment System

Acute stroke care and clinical outcomes improve substantially with stroke program

Study shows CEL-2000 vaccine blocks RA progression in mice

DURECT, Nycomed amend POSIDUR Development and License Agreement

Star Scientific seeks FDA marketing approval for Ariva-BDL dissolvable tobacco lozenge

MRI: An efficient diagnostic tool for testicular cancer

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News